"10.1371_journal.pone.0131486","plos one","2015-07-29T00:00:00Z","Charlotte D’Hulst; Inge Heulens; Nathalie Van der Aa; Karolien Goffin; Michel Koole; Kathleen Porke; Marc Van De Velde; Liesbeth Rooms; Wim Van Paesschen; Hilde Van Esch; Koen Van Laere; R Frank Kooy","Department of Medical Genetics, Antwerp University, Antwerp, Belgium; Department of Medical Genetics, University Hospital Antwerp, Antwerp, Belgium; Division of Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Leuven, Belgium; Department of Neuropsychology, University Hospitals Leuven, Leuven, Belgium; Department of Anaesthesiology, University Hospitals Leuven, Leuven, Belgium; Department of Neurology, University Hospitals Leuven, Leuven, Belgium; Center for Human Genetics, University Hospitals, Leuven and KULeuven, Leuven, Belgium","Conceived and designed the experiments: CDH IH KVL RFK. Performed the experiments: CDH IH NVDA KG MK KP MVDV LR WVP HVE KVL. Analyzed the data: CHD IH KVL RFK. Wrote the paper: CDH IH NVDA KVL RFK.","R.F.K successfully applied for funding from the FRAXA research foundation and the foundation Jerome Lejeune to cover a clinical trial with ganaxolone for the treatment of behaviors of fragile X children. Marinus Pharmaceuticals, Inc. (New Haven, CT) is the IND holder for ganaxolone and provides global regulatory support for the project. They also manage the study drug supply and have responsibility for oversight of manufacturing, labeling, shipping and stability. There are no patents, further products in development or further marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.","2015","07","Charlotte D’Hulst","CDH",12,TRUE,4,11,4,5,TRUE,FALSE,FALSE,0,NA,FALSE
